Evonik (DE:EVK)
XETRA:EVK
Want to see DE:EVK full AI Analyst Report?
Top Page
Evonik
(XETRA:EVK)
Select Model
Select Model
Rating:64Neutral
Price Target:
€18.50
▲(8.89% Upside)
Action:Reiterated
Date:05/09/26
The score is driven primarily by mixed fundamentals: stabilizing profitability and solid cash flow are offset by declining revenue and thin net margins. Technicals add support with a positive trend and balanced momentum. Valuation is helped by a strong dividend yield but held back by a relatively high P/E versus current earnings strength.
Positive Factors
Specialty, diversified business model
Evonik's focus on specialty chemicals and multiple end markets (additives, performance materials, nutrition & care) supports durable demand diversification and pricing via differentiated products and technical application support. Recurring supply relationships and application know-how underpin long-term resilience and margin support versus commodity peers.
Negative Factors
Multi-year revenue decline
A sustained top-line downtrend reduces operating leverage and limits the firm's ability to rebuild margins via scale. If underlying end-market demand or volume mix does not recover, the business may face persistent pressure on utilization, pricing leverage and long-term growth prospects.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialty, diversified business model
Evonik's focus on specialty chemicals and multiple end markets (additives, performance materials, nutrition & care) supports durable demand diversification and pricing via differentiated products and technical application support. Recurring supply relationships and application know-how underpin long-term resilience and margin support versus commodity peers.
Read all positive factors
Evonik (EVK) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€7.92B
Dividend Yield8.92%
Average Volume (3M)1.24M
Price to Earnings (P/E)50.5
Beta (1Y)0.82
Revenue Growth-9.37%
EPS Growth-47.49%
CountryDE
Employees31,585
SectorGeneral
Sector StrengthN/A
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)0.34
Shares Outstanding466,000,000
10 Day Avg. Volume1,023,876
30 Day Avg. Volume1,242,903
Financial Highlights & Ratios
PEG Ratio1.25
Price to Book (P/B)0.77
Price to Sales (P/S)0.44
P/FCF Ratio8.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€16.29Price Target Upside-4.13% Downside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)1.42
Revenue Forecast (FY)€14.46B
Evonik Business Overview & Revenue Model
Company Description
Evonik Industries AG engages in the specialty chemicals business. It operates through Specialty Additives, Nutrition & Care, Smart Materials, Performance Materials, and Technology & Infrastructure segments. The Specialty Additives segment provides...
How the Company Makes Money
Evonik makes money primarily by manufacturing and selling specialty chemical products to business customers under long-term supply relationships and recurring customer programs. Its revenue is largely generated from: (1) Additives and formulation ...
Evonik Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
67
Positive
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.72B | 14.07B | 15.16B | 15.27B | 18.49B | 14.96B |
| Gross Profit | 3.10B | 3.24B | 3.74B | 3.39B | 4.23B | 4.03B |
| EBITDA | 1.76B | 1.84B | 1.76B | 991.00M | 2.07B | 2.18B |
| Net Income | 157.00M | 265.00M | 222.00M | -465.00M | 540.00M | 746.00M |
Balance Sheet | ||||||
| Total Assets | 18.46B | 19.21B | 19.75B | 21.26B | 21.81B | 22.28B |
| Cash, Cash Equivalents and Short-Term Investments | 589.00M | 619.00M | 618.00M | 1.03B | 1.12B | 919.00M |
| Total Debt | 4.16B | 3.87B | 3.78B | 4.25B | 4.22B | 3.64B |
| Total Liabilities | 10.16B | 11.04B | 10.65B | 12.28B | 10.75B | 12.91B |
| Stockholders Equity | 8.23B | 8.11B | 9.02B | 8.91B | 10.97B | 9.29B |
Cash Flow | ||||||
| Free Cash Flow | 611.00M | 695.00M | 873.00M | 801.00M | 785.00M | 929.00M |
| Operating Cash Flow | 1.39B | 1.44B | 1.71B | 1.59B | 1.65B | 1.81B |
| Investing Cash Flow | -357.00M | -652.00M | -663.00M | -653.00M | -777.00M | -1.07B |
| Financing Cash Flow | -1.16B | -731.00M | -1.33B | -823.00M | -672.00M | -856.00M |
Evonik Technical Analysis
Neutral
16.99
Price Trends
16.84
Positive
15.46
Positive
15.04
Positive
Market Momentum
0.04
Positive
46.49
Neutral
24.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:EVK, the sentiment is Neutral. The current price of 16.99 is below the 20-day moving average (MA) of 17.47, above the 50-day MA of 16.84, and above the 200-day MA of 15.04, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 46.49 is Neutral, neither overbought nor oversold. The STOCH value of 24.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:EVK.
Evonik Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | €7.92B | 50.49 | 1.89% | 8.92% | -9.37% | -47.49% | |
63 Neutral | €8.15B | 35.33 | 5.27% | 4.30% | -9.48% | -56.88% | |
58 Neutral | €11.44B | 29.93 | 9.75% | 1.75% | -1.39% | -47.86% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | €4.79B | -9.08 | -20.12% | 3.75% | ― | ― | |
49 Neutral | €1.42B | -2.13 | -17.77% | 0.59% | -14.31% | -386.04% | |
45 Neutral | €12.42B | -17.74 | -10.04% | ― | -8.72% | -140.66% |
* General Sector Average
DE:EVK
Evonik
17.01
-2.05
-10.76%
DE:BNR
Brenntag AG
55.84
-1.87
-3.25%
DE:1COV
Covestro
59.80
-0.30
-0.50%
DE:SY1
Symrise
81.08
-22.24
-21.52%
DE:LXS
LANXESS
16.28
-10.72
-39.71%
DE:WCH
Wacker Chemie AG
99.40
36.85
58.91%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.